Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated December 5, 2025, reports on Clearmind Medicine Inc.'s efforts to regain compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders' Equity Rule. The Company previously received notice on November 3, 2025, of non-compliance due to stockholders' equity falling below the required $2,500,000 threshold.
Key Financial Metrics and Capital Activities
The filing details significant capital raising activities rather than operational financial results:
- Convertible Promissory Notes: Under agreements dated September 17, 2025, the Company issued notes with an aggregate principal of $2.5 million. Of this amount, $2.2 million was converted into 4,135,000 common shares.
- Registered Direct Offerings: In November 2025, the Company raised approximately $7.25 million in gross proceeds from the sale of common shares and pre-funded warrants.
- Warrant Exercises: As of December 3, 2025, the Company issued 2,090,987 common shares resulting from the exercise of warrants to purchase 2,894,769 shares. These warrants were previously classified as liabilities from financings in April 2023 and January 2024, which had generated aggregate gross proceeds of approximately $183,000.
The filing does not provide specific values for revenue, net profit, operating cash flow, or current debt levels outside of the note conversions mentioned.
Material Changes and Compliance Status
Based on the transactions described above, the Company believes it has regained compliance with the Minimum Stockholders' Equity Rule as of the date of this report. Nasdaq has indicated it will continue to monitor the Company's compliance. Failure to demonstrate compliance in the next periodic report could result in delisting.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the Company's belief in its regained compliance and its ability to maintain listing standards. These statements are subject to risks and uncertainties, including the possibility that actual results may differ materially from expectations. The Company explicitly states it assumes no obligation to update these statements except as required by law. The primary contingency remains the risk of delisting if the Company fails to maintain the required equity levels in future reporting periods.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance in the next periodic report to confirm sustained compliance with Nasdaq rules.
- Review the terms of the remaining unconverted portion of the $10 million convertible promissory note facility.
- Monitor for any further Nasdaq communications regarding the Company's listing status.
- Check subsequent filings for updated financial statements reflecting the impact of the $7.25 million raise and warrant exercises on the balance sheet.